3D-QSAR CoMFA studies on sulfonamide inhibitors of the Rv3588c β-carbonic anhydrase from Mycobacterium tuberculosis and design of not yet synthesized new molecules

References

• Supuran, CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467–74
   PubMed Web of Science ®Google Scholar
• Supuran CT. Therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81
   PubMed Web of Science ®Google Scholar
• Mincione F, Menabuoni L, Supuran CT. Clinical applications of the carbonic anhydrase inhibitors in ophthalmology. In: Supuran CT, Scozzafava A, Conway J, eds. Carbonic anhydrase, its inhibitors and activator. Boca Raton (FL): CRC Press; 2004
   Google Scholar
• Supuran, CT. Carbonic anhydrases: catalytic and inhibition mechanisms, distribution and physiological roles. In: Pacscas I, ed. Carbonic anhydrase and modulation of physiologic and pathologic process in the organism. Timisoara, Romania: Helicon; 1994
   Google Scholar
• Supuran CT, Scozzafava A, Casini A. Development of sulfonamide carbonic anhydrase inhibitors (CAIs). In: Supuran CT, Scozzafava A, Conway J, eds. Carbonic anhydrase, its inhibitors and activators. Boca Raton (FL): CRC Press; 2004
   Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146–89
   PubMed Web of Science ®Google Scholar
• Covarrubias AS, Larsson AM, Hogbom M, et al. Structure and function of carbonic anhydrases from Mycobacterium tuberculosis. J Biol Chem 2005;280:18782–9
   Google Scholar
• Covarrubias AS, Bergfors T, Jones TA, Hogbom M. Structural mechanics of the pH-dependent activity of beta-carbonic anhydrase from Mycobacterium tuberculosis. J Biol Chem 2006;281:4993–9
   PubMed Web of Science ®Google Scholar
• Nishimori I, Minakuchi T, Vullo D, et al. Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. J Med Chem 2009;52:3116–20
   PubMed Web of Science ®Google Scholar
• Carta F, Maresca A, Covarrubias AS, et al. Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. Bioorg Med Chem Lett 2009;19:6649–54
   PubMed Web of Science ®Google Scholar
• Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009;7:81–7
   PubMed Web of Science ®Google Scholar
• Ginsberg AM. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 2008;29:552–9
   PubMed Web of Science ®Google Scholar
• Showalter HD, Denny WA. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis 2008;88:S3–17
   PubMed Web of Science ®Google Scholar
• Tomioka H, Tatano Y, Yasumoto K, Shimizu T. Recent advances in antituberculous drug development and novel drug targets. Expert Rev Respir Med 2008;2:455–71
   PubMedGoogle Scholar
• Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007;51:35–9
   PubMed Web of Science ®Google Scholar
• Bennett JE, Izumikawa K, Marr KA. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 2004;48:1773–7
   PubMed Web of Science ®Google Scholar
• Tsai HF, Krol AA, Sarti K, Bennett JE. Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance inclinical isolates and petite mutants. Antimicrob Agents Chemother 2006;50:1384–92
   PubMed Web of Science ®Google Scholar
• Hanage WP, Fraser C, Tang J, et al. Hyper-recombination, diversity and antibiotic resistance in pneumococcus. Science 2009;324:1454–7
   Google Scholar
• Saini L, Gupta SP, Kumar Satuluri VSA. QSAR study on some series of sodium and potassium channel blockers. Med Chem 2009;5:570–6
   Google Scholar
• Singh S, Supuran CT. Chemometric QSAR modeling and in silico design of carbonic anhydrase inhibition of a coral secretory isoform by sulfonamide. Bioorg Med Chem 2013;21:495–1502
   Google Scholar
• Singh, S. A QSAR study on novel series of carbonic anhydrase inhibitors hCA IX tumor-associated (hypoxia). Med Chem 2012;8:656–72
   PubMed Web of Science ®Google Scholar
• Singh S, Supuran C T. QSARs on human carbonic anhydrase VA and VB inhibitors of some new not yet synthesized, substituted aromatic/heterocyclic sulphonamides as anti-obesity agent. J Enzyme Inhib Med Chem 2012;27:666–72
   PubMed Web of Science ®Google Scholar
• Singh S. A comparative molecular field (CoMFA) studies on carbonic anhydrase inhibitor hCA IX-tumor-associated (hypoxia). Lett Drug Des Discov 2011;8:877–83
   Google Scholar
• Singh S, Singh S, Shukla, P. Modeling of novel HIV-1 protease inhibitors incorporating N-Aryl-oxazolidinone-5-carboxamides as P2 ligands using quantum chemical and topological finger print descriptors. Med Chem Res 2011;20:1556–65
   Web of Science ®Google Scholar
• Singh S, Khadikar PV, Scozzafava A, Supuran, CT. QSAR studies for the inhibition of the transmembrane carbonic anhydrase isozyme XIV with sulfonamides using PRECLAV software. J Enzyme Inhib Med Chem 2009;24:337–49
   PubMed Web of Science ®Google Scholar
• Everitt B, Landau S, Leese M. Cluster analysis. London: Arnold Press; 2001
   Google Scholar
• BROOD (version 2.0.0), OpenEye Science Software, 3600 Cerrillos Road, Suite1107, Santa Fe, USA; 2010
   Google Scholar
• Geladi P. Notes on the history and nature of partial least squares (PLS) modeling. J Chemon 1988;2:231–46
   Google Scholar
• Cramer RD III, Bunce JD, Patterson DE. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR. Quant Struct Act Relat 1988;7:18–25
   Google Scholar